<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794143</url>
  </required_header>
  <id_info>
    <org_study_id>GRADE</org_study_id>
    <secondary_id>1U01DK098246-01</secondary_id>
    <nct_id>NCT01794143</nct_id>
  </id_info>
  <brief_title>A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes</brief_title>
  <acronym>GRADE</acronym>
  <official_title>Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GRADE Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GRADE Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used
      diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and
      patient-centered outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to HbA1c&gt;=7%, while receiving metformin and the randomly assigned study medication</measure>
    <time_frame>Quarterly for 4 to 7 years</time_frame>
    <description>The primary metabolic outcome is the time to primary failure defined as an HbA1c&gt;=7% (53mmol/mol), subsequently confirmed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to HbA1c&gt;7.5%, while receiving metformin and the randomly assigned study medication.</measure>
    <time_frame>Quarterly for 4 to 7 years</time_frame>
    <description>The secondary metabolic outcome is time to HbA1c&gt;7.5% (58 mmol/mol), confirmed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to HbA1c&gt;7.5%, while receiving study medications and basal insulin</measure>
    <time_frame>Quarterly for 4 to 7 years</time_frame>
    <description>The tertially metabolic outcome is the time to a HbA1c&gt;7.5% (58 mmol/mol), confirmed, while receiving metformin, the originally assigned medication and basal insulin.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Comparative Effectiveness of Glycemia-lowering Medications</condition>
  <arm_group>
    <arm_group_label>Sulfonylurea (glimepiride)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sulfonylurea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DPP-4 inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DPP-4 inhibitor (sitagliptin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1 receptor agonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GLP-1 receptor agonist (liraglutide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin (glargine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin (glargine), Lantus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylurea (glimepiride)</intervention_name>
    <description>Used in accordance with labeling and/or usual practice.</description>
    <arm_group_label>Sulfonylurea (glimepiride)</arm_group_label>
    <other_name>Glimepiride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPP-4 inhibitor (sitagliptin)</intervention_name>
    <description>Used in accordance with labeling and/or usual practice</description>
    <arm_group_label>DPP-4 inhibitor</arm_group_label>
    <other_name>Sitagliptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1 receptor agonist (liraglutide)</intervention_name>
    <description>Used in accordance with labeling and/or usual practice.</description>
    <arm_group_label>GLP-1 receptor agonist</arm_group_label>
    <other_name>Liraglutide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin (glargine)</intervention_name>
    <description>Used in accordance with labeling and/or usual practice.</description>
    <arm_group_label>Insulin (glargine)</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women diagnosed with diabetes at age ≥ 30 years (≥ 20 for American Indians)

          2. Duration of diagnosed diabetes &lt; 10 years

          3. HbA1c criteria (at final run-in visit, ~2 weeks prior to randomization): 6.8-8.5%

          4. Taking a daily dose of ≥ 1000 mg metformin for a minimum of 8 weeks at final run-in

          5. Willingness to administer daily subcutaneous injections, take a second diabetes drug
             after randomization, potentially initiate insulin and intensify insulin therapy if
             study metabolic goals are not met, perform self-monitoring of blood glucose

          6. Fluent in either English or Spanish

          7. A negative pregnancy test for all females of childbearing potential (i.e.
             pre-menopausal, and not surgically sterile)

          8. Provision of signed and dated informed consent prior to any study procedures

        Exclusion Criteria:

          1. Suspected type 1 diabetes (lean with polyuria, polydipsia, and weight loss with little
             response to metformin) or &quot;secondary&quot; diabetes due to specific causes (e.g. previously
             diagnosed monogenic syndromes, pancreatic surgery, pancreatitis)

          2. Current or previous (within past 6 months) treatment with any diabetes
             drug/glucose-lowering medication other than metformin (limited use of no longer than
             seven days is allowed, for example during hospitalization)

          3. More than 10 years of treatment with metformin at time of randomization screening

          4. History of intolerance or allergy or other contraindications to any of the proposed
             study medications

          5. Resides in the same household with another GRADE study participant

          6. Current need for any specific glucose-lowering medications solely for other
             conditions, for example for polycystic ovary syndrome

          7. Symptomatic hyperglycemia requiring immediate therapy during screening or run-in, in
             the judgment of the physician

          8. A life-threatening event within 30 days prior to screening or currently planned major
             surgery

          9. Any major cardiovascular event in previous year, including history of myocardial
             infarction, stroke, or vascular procedure such as coronary artery or peripheral bypass
             grafting, stent placements (peripheral or coronary) or angioplasty.

         10. Plans for pregnancy during the course of the study for women of child-bearing
             potential

         11. History of or planning bariatric surgery, including banding procedures or surgical
             gastric and/or intestinal bypass (if banding removed, may be considered eligible after
             1 year)

         12. History of congestive heart failure (NYHA 3 or greater)

         13. History of pancreatitis

         14. History of cancer, other than non-melanoma skin cancer, that required therapy in the 5
             years prior to randomization

         15. Personal or family history of MEN-2 or family history of medullary thyroid cancer

         16. Estimated GFR (eGFR) &lt;30 ml/min/1.73 m2 or end stage renal disease requiring renal
             replacement therapy

         17. History of severe liver disease or acute hepatitis or ALT &gt; 3 times upper limit of
             normal

         18. Current alcoholism or excessive alcohol intake

         19. Previous organ transplant

         20. Treatment with oral or systemic glucocorticoids (other than short-term treatment, for
             example for poison ivy) or disease likely to require periodic or regular
             glucocorticoid therapy (inhaled steroids are allowed)

         21. Treatment with atypical antipsychotics

         22. History of hemolytic anemia, chronic transfusion requirement, or other condition
             rendering HbA1c results unreliable as indicator of chronic glucose levels, or
             hematocrit &lt;35 for males and &lt;33 for females

         23. Clinically or medically unstable with expected survival &lt;1 year

         24. Unwillingness to permit sites to contact the PCP to communicate information about the
             study and the participant's data

         25. No non-study PCP or inability to identify such a PCP (who will provide non-study care)
             by the time of final run-in

         26. Participation in another interventional clinical trial

         27. Previous randomization in the GRADE study

         28. In the opinion of the principal investigator (PI), any other factor, including
             language barrier, likely to limit compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Nathan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama-Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwestern American Indian Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Medical Research Foundation, San Diego (San Diego VA)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida VA Foundation (Miami VA)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente of Georgia</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Health Research and Education Institute (VA Pacific Islands)</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico School of Medicine</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York (SUNY)-Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Naomi Berrie Diabetes Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai St. Luke's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Diabetes Care Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University School of Medicine</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas-Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Institute for Biomedical and Clinical Research</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of Type 2 diabetes</keyword>
  <keyword>Comparative effectiveness research</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>Patient-centered outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

